PSD psivida limited

uk listing here we come

  1. 7,519 Posts.
    lightbulb Created with Sketch. 381
    ASX RELEASE 9 September 2003
    UK broker appointed to list pSiMedica
    Australian nanotechnology company pSivida Limited (ASX: PSD) is pleased to announce Evolution Beeson Gregory Ltd (“EVBGL”) has been appointed to assist with the listing of its UK operating subsidiary, pSiMedica on the London Stock Exchange (“LSE”).
    EVBGL has been mandated to assist pSiMedica with its upcoming listing on either the main board of the LSE or the Alternative Investment Market (“AIM”). It is anticipated that the listing will occur no later than September 2004.
    Importantly the listing will provide pSiMedica with access to significant overseas capital markets, increased support from European Institutions and further coverage and support of the BioSiliconTM technology.
    Mr Nick Rodgers, Director of EVBGL, said “pSiMedica has developed some very interesting technology which has very exciting prospects in a number of therapeutic and other applications and we are pleased to be associated with the Company.”
    pSivida Managing Director Mr Gavin Rezos said, “We are pleased to have the assistance of EVBGL in listing pSiMedica. EVBGL are a well respected investment house and have a strong association with nanotechnology. They have significant experience and expertise in listing companies in the UK with a well established institutional network. We look forward to working with them closely in what is a significant milestone for the company.”
    EVBGL is the investment banking business of UK listed Evolution Group plc providing equity research, institutional sales & trading and corporate finance advice.
    At the time of listing it is expected that pSivida will have its own BioSiliconTM product lines, such that pSivida shareholders will retain an interest in pSivida as well as an intention for them to receive pSiMedica script. Details of the listing and how pSivida shareholders may be able to participate directly in the offering will be provided closer to the listing date.
    Released by:
    Josh Mann
    Investor Relations
    pSivida Limited
    Tel: + 61 8 9226 5099
    [email protected]
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.